Article · 2014
Review articlePublished 3 May 2019
Target identification and validation for diabetic nephropathy using molecular docking studies
Abstract
Select any words in the title or abstract, or press this and choose a sentence.
Diabetic nephropathy is one of the chronic complications of diabetes mellitus. Inflammatory mediators are believed to play a vital role as predictors of low grade systemic inflammation in diabetic nephropathy. Drug designing, one of the hottest topics have found its new pathway to create a history in the field of medical science. The lead compound analysis starts with CADD, assisting to identify and to optimize the right compound. The technique helps in generating a suitable compound specific to the disease; thereby an effective treatment is achieved. Molecular modeling method has been used for modeling a new molecule for Diabetic nephropathy using Lisinopril , a drug that’s already designed. This drug is drawn using hyperchem, and its R group is modified by replacing different functional groups like OH, Br, CH2CH3, CH3, Cl, F, H, and NH2 , etc in its place and docked by using gold software.. The molecules designed as such are optimized using different algorithms and their affinity is checked with protein. The binding free energy of the protein is calculated by performing docking process. The molecule with minimum binding energy will have the maximum binding affinity. The binding free energy is calculated by the formula Z = Sum of the energy of optimized ligand devoid of solvation parameters and the energy of the protein - ligand optimization. The binding free energy of the designed molecules is obtained by eliminating the energy of the main molecule i.e. Lisinopril .From the results obtained it’s clear that ligand 1 & 5 ( -3.65 & -2.73 ) for Diabetic nephropathy have the maximum binding affinity. So these molecules are determined as the best lead molecules targeting computationally.
Subjects
Pharmaceutical SciencesAsk about this article
Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.
Similar by topic
Article · 2012
ADMET, Docking studies and binding energy calculations of some Novel ACE - inhibitors for the treatment of Diabetic Nephropathy
Article · 17 May 2024
Validation of Protective Effect of Shenqi Compound on Aging-Related Diabetic Nephropathy: Evidence from Network Pharmacology and Experimental Exploration for MPC5 Cell Line
Article · 20 Feb 2024
Targeted Regulating of TGFBR1 Expression by Bone Marrow Mesenchymal Stem Cell-Derived Exosome Let-7a and its Mechanism in Diabetic Nephropathy Rats
Article · 29 Nov 2023
Nephroprotective Activity of Rutin in Diabetic Nephropathy Rat Model Targeting Nitric Oxide Pathway
More from this journal
The newest in Der Pharma Chemica.
Article · 22 Sep 2026
Synthesis and Characterization of Ibuprofen Impurities-A, F, Q and R
Article · 22 Aug 2026
Synthesis of Some New Heterocyclic Compounds Derived from 2-Chlorobenzoic Acid as Potential Biological Activity
Article · 17 Jun 2026
Formulation and Characterization of Orlistat Fast Dissolving Tablets
Conferences in this field
Upcoming conferences in this field.
Follow
New articles from what you follow go into your email digest, once you agree to alert emails.
- JournalDer Pharma Chemica
- SubjectPharmaceutical Sciences
- BylineArticles whose byline prints “Ramanjaneyulu M.”
- BylineArticles whose byline prints “K. Ananth Kumar”
- BylineArticles whose byline prints “M. Shubash Kumar”
- BylineArticles whose byline prints “Shivakanth Reddy”
- BylineArticles whose byline prints “Divyadhatri Kara”
- BylineArticles whose byline prints “Pravallika Mukthala”
- BylineArticles whose byline prints “Rohith Raj”
- BylineArticles whose byline prints “Chandaka Madhu”
